Incidence and development of cholestasis in surgical neonates receiving an intravenous mixed-oil lipid emulsion.

Lumeng J YuLorenzo Anez-BustillosPaul D MitchellVictoria H KoJordan D SecorAlexis P HurleyDuy T DaoScott C FligorBennet S ChoSavas T TsikisKathleen M Gura Mark Puder

Published in: JPEN. Journal of parenteral and enteral nutrition (2022)

In surgical neonates, MOLE may not prevent cholestasis and should not be considered hepatoprotective. Regardless of ILE source, all surgical neonates should be closely monitored for development of IFALD. To date, there is still no ILE able to prevent IFALD.

Keyphrases

low birth weight
risk factors
drug induced
high dose
preterm infants